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Abstract
Myeloid sarcoma of the urinary bladder is a rare disorder. We report a 71-year-old man with hematuria who had a diffuse 
myeloid sarcoma of the bladder. He was also under follow-up for unclassified myeloproliferative/myelodysplastic disorder, 
diagnosed two months before. Abdominal ultrasonography and computed tomography findings were normal. Diagnostic 
cystoscopy revealed patchy areas of mucosal swelling with hyperemia. Histopathological examination of biopsies demon-
strated a neoplasm composed of blasts showing myeloperoxidase positivity by immunohistochemistry. To our knowledge, 
the current case is the first case of myeloid sarcoma in the urinary bladder without evidence of a mass lesion, with a 
concurrent diagnosis of unclassifiable myelodysplastic/myeloproliferative disease. (Turk J Hematol 2009; 26: 90-2)
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Özet
Myeloid sarkom mesanede nadir görülen bir hastalıktır. Bu vaka takdiminde hematüri ile başvuran ve 2 ay önce 
sınıflandırılamayan myeloproliferatif/myelodisplastik hastalık tanısı almış 71 yaşında erkek hastada mesanede diffüz tutulum 
ile seyreden myeloid sarkom tanımlandı. Hastanın batın ultrasonografisi ve tomografisi normal olup, tanısal amaçlı sistosko-
pide hiperemik ve ödemli bir mukoza izlendi. Alınan mukozal örneklerin histopatolojik incelemesinde immünhistokimyasal 
olarak myeloperoksidaz ile boyanma gösteren blastik hücreler saptandı. Sınıflandırılamayan myeloproliferatif/myelodisplas-
tik hastalık ile kitle olmaksızın mesanede granulositik sarkom izlenen ilk vaka olarak tanımlandı ve literatür eşliğinde tartışıldı. 
(Turk J Hematol 2009; 26: 90-2)
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Myeloid sarcoma (MS) is a collection of myeloblasts or 
immature myeloid cells in extramedullary sites. The lesion may 
precede or occur concurrently with acute or chronic myeloid 
leukemia or the other types of myeloproliferative or myelodys-
plastic syndromes. The most common sites of involvement are 
soft tissue, orbit, lymph nodes and skin [1]. 
We present a rare case with both MS of the urinary bladder 
with patchy areas of submucosal involvement and an unclassi-
fied myelodysplastic/myeloproliferative disease. 
Case Report
A 71-year-old man was admitted to the hospital with fatigue 
and weakness. Physical examination was unremarkable except 
for pallor. Laboratory parameters were as follows: hemoglobin 
(Hb) 7 g/dl, platelets 130x109/L and white blood cell (WBC) 
count 18x109/L with 70% neutrophils, 20% lymphocytes, 4% 
myelocytes, 2% normoblasts, 2% blasts, and 1% monocytes 
in the blood smear. Other laboratory investigations including 
urea, electrolytes and liver function tests were all in normal 
limits. Bone marrow aspiration and biopsy demonstrated 
marked myeloid hyperplasia with maturation and poor granula-
tion of granulocytes, and normal number of blast cells (Figures 
1, 2). Bcr/abl fusion gene was negative. The patient was 
accepted as unclassified myelodysplastic/myeloproliferative 
disease. The diagnosis of myelodysplastic/myeloproliferative 
disease, unclassifiable was based on bone marrow aspiration 
and biopsy examination (hypercellularity and marked myeloid 
hyperplasia with maturation), molecular study (bcr/abl gene 
fusion negativity), and laboratory and clinical findings (refrac-
tory anemia, leukocytosis, absence of monocytosis and hepa-
tosplenomegaly, and no history of recent cytotoxic or growth 
factor therapy). No specific treatment was planned except 
blood transfusion when necessary.
Approximately two months later while under routine follow-
up, the patient suffered hematuria. Anemia (Hb <8 g/dl) and leu-
kocytosis (34x109/L) were still present. Abdominal ultrasonogra-
phy and computed tomography (CT) of the abdomen were nor-
mal (Figure 3). Diagnostic cystoscopy revealed scattered ery-
thematous mucosal hyperemia and swelling without any mass 
lesion. Biopsies were performed. Histological examination dem-
onstrated a dense cellular infiltrate composed of immature cells 
under normal mucosal epithelium (Figure 4). The neoplastic cells 
were mostly medium in size with vesicular, round nuclei. The 
tumor cells were stained positive for myeloperoxidase (Figures 5, 
6) and negative for cytokeratin, CD20, CD3, vimentin, and S-100 
protein. No other foci of infiltration were detectable at the time of 
diagnosis or during follow-up. During follow-up, no other specific 
treatment modality in relation to hematological disease was 
planned due to the patient’s older age.
Discussion
Myeloid sarcoma is a collection of immature myeloid cells 
and was first described by Burns in 1811. MS was referred to as 
chloroma by King in 1853 due to its grossly green color when 
exposed to the air. This term was replaced with MS by Rappaport 
in 1966. In the new World Health Organization (WHO) classifica-
tion, the term MS is used to define a tumor of myeloblasts or 
immature myeloid cells occurring in an extramedullary site [1]. 
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Figure 1. Hypercellular bone marrow biopsy with myeloid hyperplasia 
Figure 2. Bone marrow aspiration with poor granulation of granulocyte
Figure 3. Computed tomography of the urinary bladder demon-
strates normal thickness     Most MS cases occur in patients with a history of acute myeloid 
leukemia (AML), myeloproliferative disorder, or a myelodysplastic 
syndrome; however, it is rarely seen prior to the onset of bone 
marrow disease. The most common sites of involvement are soft 
tissue, lymph nodes, skin, periosteum and bone. Infrequently, it 
has been reported in other sites, such as the mediastinum, 
breast, orbit, uterus, epididymis, and gallbladder [2-4]. 
MS involving the urinary bladder is rare. In our review of the 
medical literature in English, we identified eight cases of MS 
involving the urinary bladder [2,3,5-9]. No cases were reported 
to have patchy submucosal involvement without any mass 
lesion, and there has been no reported association with myelo-
dysplastic/myeloproliferative disease, unclassifiable. In the cur-
rent case, abdominal CT demonstrated normal thickness of 
the urinary bladder wall and no mass lesion. Diagnostic cystos-
copy demonstrated areas of patchy mucosal hyperemia.
MS is generally composed of poorly differentiated blasts 
and immature cells. The major differential diagnoses are large 
cell lymphoma, Burkitt lymphoma, lymphoblastic lymphoma 
and undifferentiated round cell tumor. Immunophenotyping by 
immunohistochemistry for expression of myeloid markers such 
as myeloperoxidase is essential for diagnosis of MS [10].
To our knowledge, this is the first report of a case with MS 
with diffuse infiltration of the urinary bladder and unclassified 
myelodysplastic/myeloproliferative disease. MS of the urinary 
bladder should be suspected in patients presenting with hema-
turia having myeloid leukemia and myeloproliferative or myelo-
dysplastic syndromes, and even when associated with unclassi-
fied myelodysplastic/myeloproliferative disease, as in our case. 
Cystoscopic examination and biopsy of any suspicious mucosal 
lesion should be performed in the absence of any mass lesion in 
the urinary bladder in patients under follow-up for this diagnosis.
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Figure 4. Immature myeloid cell infiltration in submucosa of urinary 
bladder   
Figure 5-6. Positive staining of neoplastic cells with myeloperoxi-